Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Operating expenses
Research and development	$ 78,568	$ 25,189	$ 15,265
General and administrative	105,861	13,481	9,844
Change in fair value of contingent consideration	3,242	2,714	(712)
Total operating expenses	187,671	41,384	24,397
Operating loss	(187,671)	(41,384)	(24,397)
Other income (expense), net
Change in fair value of warrant liability	0	(182)	30
Interest income, net	12,052	2,578	300
Interest expense	(231)	0	0
Total other income (expense), net	11,821	2,396	330
Net loss	(175,850)	(38,988)	(24,067)
Other comprehensive income (loss)
Net unrealized gain on marketable securities	361	0	0
Total comprehensive loss	$ (175,489)	$ (38,988)	$ (24,067)
Net loss per common share basic	$ (4.38)	$ (2.36)	$ (2.87)
Net loss per common share diluted	$ (4.38)	$ (2.36)	$ (2.87)
Weighted-average common shares outstanding used to calculate basic net loss per common share	40,175,926	16,492,132	8,397,088
Weighted-average common shares outstanding used to calculate diluted net loss per common share	40,175,926	16,492,132	8,397,088